Feb. 12, 2013
Peter R. Farina, Ph.D. and David W. Keiser, the two co-chairs of CURE (Connecticut United for Research Excellence), the state bioscience organization, today released the following statement about organizational changes at CURE.
After ten years at the helm,
, the current President and CEO of CURE, has decided to step back from that role so that he can dedicate some additional time to private business ventures and other non-life sciences policy issues. Paul has made great strides for CURE and so we are pleased to report that he has agreed to continue to coordinate our government relations efforts as Chair of the CURE BioScience Growth Council and as a CURE Board and Executive Committee member. This arrangement will allow Paul to bring even greater focus and depth to CURE's life sciences advocacy.
The state has recently increased its investment in the life sciences and in entrepreneurship. For example, it has invited The Jackson Laboratory to develop
a genomic medicine facility in Farmington
Connecticut's Innovation Ecosystem
, a public-private partnership, with hubs in
, to support high-value technology-based start-up and stage 2 companies. Furthermore, Governor Malloy has proposed a new
Bioscience Innovation Act
and announced a
(Science, Technology, Engineering and Math) education activities.
CURE seeks to strengthen and enhance its mission to support these efforts. To do so most effectively, and build on Paul's success, it is our great pleasure to announce that a good friend of the
life sciences community, Dr.
, has agreed to assume the position of Chief Executive Officer and President of CURE, effective
. Susan is well-known to the CURE community and has a wealth of experience that makes her an ideal choice to lead the organization.
Susan is an experienced scientist, mentor, entrepreneur and investor with skill at connecting academic expertise and technology with the commercial sector. She is currently Director of the Technology Exchange Portal at the
University of Connecticut
's Office of Economic Development. In this role Susan assists
-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connects ideas with business expertise, business plans with investors and industry with scholars.
Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded in
in 2000. Under her leadership, Rib-X raised more than
in private equity, bridge financing and government grants and built a robust pipeline of antibiotics to treat serious hospital infections. Prior to Rib-X, Susan served as a member of Pfizer's Strategic Alliance Group where she was key to the creation of a
investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery.
Susan received a Ph.D. in Microbiology and Molecular Genetics from
and a B. A. from
. She performed post-doctoral research at
Yale Medical School
in the Department of Cell Biology as a
Jane Coffin Child
Susan will initially focus on expanding the CURE network, fostering connectivity among members, educators, investors and entrepreneurs, helping to build the bridges necessary to transform cutting edge bioscience research into funded, sustainable start-up biotechs as well as fortifying CURE's commitment to education.